Literature DB >> 19474811

siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model.

E Gonzalez-Gonzalez1, H Ra, R P Hickerson, Q Wang, W Piyawattanametha, M J Mandella, G S Kino, D Leake, A A Avilion, O Solgaard, T C Doyle, C H Contag, R L Kaspar.   

Abstract

Small interfering RNAs (siRNAs) can be designed to specifically and potently target and silence a mutant allele, with little or no effect on the corresponding wild-type allele expression, presenting an opportunity for therapeutic intervention. Although several siRNAs have entered clinical trials, the development of siRNA therapeutics as a new drug class will require the development of improved delivery technologies. In this study, a reporter mouse model (transgenic click beetle luciferase/humanized monster green fluorescent protein) was developed to enable the study of siRNA delivery to skin; in this transgenic mouse, green fluorescent protein reporter gene expression is confined to the epidermis. Intradermal injection of siRNAs targeting the reporter gene resulted in marked reduction of green fluorescent protein expression in the localized treatment areas as measured by histology, real-time quantitative polymerase chain reaction and intravital imaging using a dual-axes confocal fluorescence microscope. These results indicate that this transgenic mouse skin model, coupled with in vivo imaging, will be useful for development of efficient and 'patient-friendly' siRNA delivery techniques and should facilitate the translation of siRNA-based therapeutics to the clinic for treatment of skin disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19474811     DOI: 10.1038/gt.2009.62

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  25 in total

1.  In vivo sustained release of siRNA from solid lipid nanoparticles.

Authors:  Tatsiana Lobovkina; Gunilla B Jacobson; Emilio Gonzalez-Gonzalez; Robyn P Hickerson; Devin Leake; Roger L Kaspar; Christopher H Contag; Richard N Zare
Journal:  ACS Nano       Date:  2011-11-18       Impact factor: 15.881

2.  Silencing of reporter gene expression in skin using siRNAs and expression of plasmid DNA delivered by a soluble protrusion array device (PAD).

Authors:  Emilio Gonzalez-Gonzalez; Tycho J Speaker; Robyn P Hickerson; Ryan Spitler; Manuel A Flores; Devin Leake; Christopher H Contag; Roger L Kaspar
Journal:  Mol Ther       Date:  2010-06-22       Impact factor: 11.454

3.  Differential fates of biomolecules delivered to target cells via extracellular vesicles.

Authors:  Masamitsu Kanada; Michael H Bachmann; Jonathan W Hardy; Daniel Omar Frimannson; Laura Bronsart; Andrew Wang; Matthew D Sylvester; Tobi L Schmidt; Roger L Kaspar; Manish J Butte; A C Matin; Christopher H Contag
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

4.  Intravital fluorescence imaging of small interfering RNA-mediated gene repression in a dual reporter melanoma xenograft model.

Authors:  Robyn P Hickerson; Emilio Gonzalez-Gonzalez; Alexander V Vlassov; Mu Li; Maria Fernanda Lara; Christopher H Contag; Roger L Kaspar
Journal:  Nucleic Acid Ther       Date:  2012-10-25       Impact factor: 5.486

5.  Designed guanidinium-rich amphipathic oligocarbonate molecular transporters complex, deliver and release siRNA in cells.

Authors:  Erika I Geihe; Christina B Cooley; Jeff R Simon; Matthew K Kiesewetter; Justin A Edward; Robyn P Hickerson; Roger L Kaspar; James L Hedrick; Robert M Waymouth; Paul A Wender
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-30       Impact factor: 11.205

6.  Guanidinium-rich, glycerol-derived oligocarbonates: a new class of cell-penetrating molecular transporters that complex, deliver, and release siRNA.

Authors:  Paul A Wender; Melanie A Huttner; Daryl Staveness; Jessica R Vargas; Adele F Xu
Journal:  Mol Pharm       Date:  2015-01-27       Impact factor: 4.939

7.  Disruption of cytokeratin-8 interaction with F508del-CFTR corrects its functional defect.

Authors:  Julien Colas; Grazyna Faure; Emilie Saussereau; Stéphanie Trudel; Wael M Rabeh; Sara Bitam; Ida Chiara Guerrera; Janine Fritsch; Isabelle Sermet-Gaudelus; Noëlie Davezac; Franck Brouillard; Gergely L Lukacs; Harald Herrmann; Mario Ollero; Aleksander Edelman
Journal:  Hum Mol Genet       Date:  2011-10-28       Impact factor: 6.150

8.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

Authors:  Sancy A Leachman; Robyn P Hickerson; Mary E Schwartz; Emily E Bullough; Stephen L Hutcherson; Kenneth M Boucher; C David Hansen; Mark J Eliason; G Susan Srivatsa; Douglas J Kornbrust; Frances Jd Smith; Wh Irwin McLean; Leonard M Milstone; Roger L Kaspar
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

9.  Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs.

Authors:  Qing Ge; Anne Dallas; Heini Ilves; Joshua Shorenstein; Mark A Behlke; Brian H Johnston
Journal:  RNA       Date:  2009-11-30       Impact factor: 4.942

10.  Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept.

Authors:  Rosalind H E Chong; Emilio Gonzalez-Gonzalez; Maria F Lara; Tycho J Speaker; Christopher H Contag; Roger L Kaspar; Sion A Coulman; Rachel Hargest; James C Birchall
Journal:  J Control Release       Date:  2013-01-08       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.